一种可接受的缓释磷酸盐制剂“慢磷” 。
An acceptable slow-release phosphate preparation "slow P".
作者信息
Parsons V, Porter A, Lund C
出版信息
Postgrad Med J. 1970 Jul;46(537):417-21. doi: 10.1136/pgmj.46.537.417.
Abstract
Slow P has been an acceptable form of oral phosphate therapy in a series of patients with a variety of bone disease. Therapeutic responses have been achieved in a number of patients without side effects together with minor elevation of the serum and urinary phosphate in the majority of patients. Some patients have continued with such supplements for several months which encourages an extended trial under more stringent conditions.
摘要
在一系列患有各种骨病的患者中，慢释磷酸盐已成为一种可接受的口服磷酸盐治疗形式。许多患者取得了治疗效果且无副作用，大多数患者的血清和尿磷酸盐略有升高。一些患者持续服用此类补充剂数月，这促使在更严格的条件下进行更长时间的试验。
相似文献
1
An acceptable slow-release phosphate preparation "slow P".一种可接受的缓释磷酸盐制剂“慢磷” 。
Postgrad Med J. 1970 Jul;46(537):417-21. doi: 10.1136/pgmj.46.537.417.
2
Formulation studies on slow-release phosphate tablets for high-dosage administration in renal transplant patients [proceedings].
J Pharm Pharmacol. 1976 Dec;28 Suppl:68P.
3
Radiocalcium and radiophosphate studies after thyrocalcitonin in man.人使用降钙素后的放射性钙和放射性磷酸盐研究。
Helv Med Acta. 1969 Nov;35(2):96-102.
4
[Action of corticoids on urinary excretion of calcium, inorganic phosphates and hydroxyproline].
Minerva Med. 1969 Jan 20;60(6):165-70.
5
Bisphosphonates in clinical oncology. The development of pamidronate.
Recent Results Cancer Res. 1999;149:1-113.
6
Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria.
J Urol. 1998 May;159(5):1451-5; discussion 1455-6. doi: 10.1097/00005392-199805000-00006.
7
Physicochemical effects of a new slow-release potassium phosphate preparation (UroPhos-K) in absorptive hypercalciuria.
J Bone Miner Res. 1995 Mar;10(3):394-400. doi: 10.1002/jbmr.5650100309.
8
[Clinical trial of a new long-acting salicylate].
Mars Med. 1967;104(4):379-82.
9
[Bowel preparation for colonoscopy: comparative study using Boston Bowel Preparation Scale].[结肠镜检查的肠道准备：使用波士顿肠道准备量表的比较研究]
Acta Gastroenterol Latinoam. 2012 Sep;42(3):186-92.
10
[Clinical trial of the calcitonin hormone in orthopedic pathology and trauma].
Chir Organi Mov. 1977;63(6):551-7.
本文引用的文献
1
STUDIES IN PARATHYROID PHYSIOLOGY: III. The Effect of Phosphate Ingestion in Clinical Hyperparathyroidism.甲状旁腺生理学研究：III. 磷摄入对临床甲状旁腺功能亢进的影响。
J Clin Invest. 1932 Mar;11(2):411-35. doi: 10.1172/JCI100423.
2
CLINICAL EXPERIENCE WITH RENAL TRANSPLANTATION.肾移植的临床经验
Br J Urol. 1965 Aug;37:370-9. doi: 10.1111/j.1464-410x.1965.tb09612.x.
3
EFFECT OF ORTHOPHOSPHATE ON URINARY PYROPHOSPHATE EXCRETION AND THE PREVENTION OF UROLITHIASIS.正磷酸盐对尿焦磷酸盐排泄及尿石症预防的作用
Lancet. 1964 May 16;1(7342):1065-7. doi: 10.1016/s0140-6736(64)91267-x.
4
THE TUBULAR MAXIMAL RESORPTIVE RATE FOR INORGANIC PHOSPHATE IN NORMAL SUBJECTS.正常受试者对无机磷酸盐的肾小管最大重吸收率
Clin Sci. 1963 Dec;25:431-41.
5
TREATMENT OF THE ADULT FANCONI SYNDROME WITH ORAL PHOSPHATE SUPPLEMENTS AND ALKALI. REPORT OF TWO CASES ASSOCIATED WITH NEPHROLITHIASIS.口服磷酸盐补充剂和碱治疗成人范科尼综合征。两例合并肾结石的报告。
Am J Med. 1963 Oct;35:487-511. doi: 10.1016/0002-9343(63)90148-7.
6
Some problems of hyperparathyroidism.甲状旁腺功能亢进的一些问题。
Br Med J. 1962 Dec 8;2(5318):1495-500. doi: 10.1136/bmj.2.5318.1495.
7
A specific method for the analysis of hydroxyproline in tissues and urine.一种用于分析组织和尿液中羟脯氨酸的特定方法。
Anal Biochem. 1960 Nov;1:228-39. doi: 10.1016/0003-2697(60)90050-6.
8
The treatment of adult phosphate diabetes and Fanconi syndrome with neutral sodium phosphate.用中性磷酸钠治疗成人磷酸盐糖尿病和范科尼综合征。
Am J Med. 1967 Oct;43(4):508-43. doi: 10.1016/0002-9343(67)90177-5.
9
Inorganic phosphate treatment of hypercalcemia of diverse etiologies.无机磷酸盐治疗多种病因所致的高钙血症。
N Engl J Med. 1966 Jan 6;274(1):1-7. doi: 10.1056/NEJM196601062740101.
10
Effects of varying phosphate intake in primary hyperparathyroidism.原发性甲状旁腺功能亢进症中不同磷摄入量的影响。
J Clin Endocrinol Metab. 1968 May;28(5):651-60. doi: 10.1210/jcem-28-5-651.
Zotero 插件